Shanghai Registry of Acute Coronary Events

Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00713557

Enrollment

20000

Registered

2008-07-11

Start date

2005-03-31

Completion date

Unknown

Last updated

2016-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Coronary Artery Disease

Keywords

coronary angioplasty

Brief summary

SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.

Detailed description

consecutive patients with STEMI who presented symptoms within 12 hours and treated by primary PCI in Shanghai, were enrolled in the prospective sysytem. Several strategies were applied in these patients, including physician vs. patient transfer strategy, upsteam vs. downstream strategy, Firebird stent vs. Excel stent (bio-absorbable SES), etc. Once the patient was randomized to one of these study, he will be denied to the others. Clinical and angiographic outcomes were compared, with the final purpose to find an optimal strategy in treating AMI patients.

Interventions

DEVICEdrug-eluting stent

drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

DRUGTirofiban

upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment

Exclusion criteria

* non ACS patients; * complicated with other lethal disease * predicted life span less than 12 months * known allergy history to any anti-platelet or anti-thrombin medicine * unconscious at the time of arrival at the hospital

Design outcomes

Primary

Measure	Time frame
major adverse cardiac events(MACE), including death, non-fatal re-MI, and target vessel revascularization	in-hospital, 30d, and long-term follow-up

Secondary

Measure	Time frame
stroke, stent thrombosis	in-hospital, 30d, and long-term follow-up

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026